09:24 AM EDT, 03/23/2026 (MT Newswires) -- Tarsus Pharmaceuticals ( TARS ) said Monday it became eligible to receive a $15 million milestone payment after the regulatory approval of lotilaner ophthalmic solution TP-03 0.25% to treat Demodex blepharitis in China.

The company said Grand Pharmaceutical Group, its partner for the development and commercialization of TP-03 in the Greater China region, obtained the approval from China's National Medical Products Administration.

Tarsus said the regulatory approval as well as the patent issuance related to TP-03 were the conditions required for the milestone payment under its agreement with Grand Pharmaceutical.

The company said it is also eligible for further payments tied to additional regulatory milestones, China-based TP-03 sales threshold milestones, and tiered royalties for product sales in the Greater China region.

TP-03 is marketed as Xdemvy in the US, Tarsus said.